HHS, Regeneron Come To ‘Reasonable Pricing Agreement’ For NexGen Drug

By Maaisha Osman / September 8, 2023 at 7:20 PM

HHS hammered out a contract agreement with Regeneron that ensures the company’s NexGen monoclonal antibody drug will be available in the United States at a price that matches or is lower than its counterparts in comparable international markets, the department revealed Friday (Sept. 8).


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.